thiotepa has been researched along with Benign Optic Nerve Neoplasm in 2 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ferreri, AJ | 1 |
Cwynarski, K | 1 |
Pulczynski, E | 1 |
Ponzoni, M | 1 |
Deckert, M | 1 |
Politi, LS | 1 |
Torri, V | 1 |
Fox, CP | 1 |
Rosée, PL | 1 |
Schorb, E | 1 |
Ambrosetti, A | 1 |
Roth, A | 1 |
Hemmaway, C | 1 |
Ferrari, A | 1 |
Linton, KM | 1 |
Rudà, R | 1 |
Binder, M | 1 |
Pukrop, T | 1 |
Balzarotti, M | 1 |
Fabbri, A | 1 |
Johnson, P | 1 |
Gørløv, JS | 1 |
Hess, G | 1 |
Panse, J | 1 |
Pisani, F | 1 |
Tucci, A | 1 |
Stilgenbauer, S | 1 |
Hertenstein, B | 1 |
Keller, U | 1 |
Krause, SW | 1 |
Levis, A | 1 |
Schmoll, HJ | 1 |
Cavalli, F | 1 |
Finke, J | 1 |
Reni, M | 1 |
Zucca, E | 1 |
Illerhaus, G | 1 |
Heath, JA | 1 |
Broxson, EH | 1 |
Dole, MG | 1 |
Filippa, DA | 1 |
George, D | 1 |
Lyden, D | 1 |
Dunkel, IJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra[NCT01011920] | Phase 2 | 126 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for thiotepa and Benign Optic Nerve Neoplasm
Article | Year |
---|---|
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Topics: Acute Kidney Injury; Anemia; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System | 2016 |
1 other study available for thiotepa and Benign Optic Nerve Neoplasm
Article | Year |
---|---|
Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Ph | 2002 |